Shots:

• Lundbeck acquires Alder BioPharmaceuticals in the all-cash transaction making a total deal value $1.95B. Alder to receive $18/share as upfront- non-tradeable CVR of $2/share on EMA’s approval of Eptinezumab with 79% premium to Alder’s shareholders based on the closing price on Sept 13- 2019. The transaction is expected to be close in Q4’19
• The focus of the acquisition is to enhance Lunbeck’s neurology portfolio with the expected US launch of Alder’s Eptinezumab (IV) for the prevention of episodic and chronic migraine in 2020 and gain access to Alder’s mAb expertise with the addition of its ALD1910- an early stage Ab
• Eptinezumab is an investigational mAb- administered as a quarterly 30-minute IV infusion with its expected BLA submission in Feb’2019 and PDUFA date as Feb 21- 2020 and anticipated regulatory submission to EMA in 2020 following submission in other regions including China & Japan

Click here to­ read full press release/ article | Ref: Alder BioPharmaceutical | Image: Ticker